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Low-dose tamoxifen treatment 
in juvenile males has long-term 
adverse effects on the reproductive 
system: implications for inducible 
transgenics
Saloni H. Patel1, Laura O’Hara1, Nina Atanassova  2, Sarah E. Smith1, Michael K. Curley1, 
Diane Rebourcet1, Annalucia L. Darbey1, Anne-Louise Gannon1, Richard M. Sharpe1 &  
Lee B. Smith1,3
The tamoxifen-inducible Cre system is a popular transgenic method for controlling the induction of 
recombination by Cre at a specific time and in a specific cell type. However, tamoxifen is not an inert 
inducer of recombination, but an established endocrine disruptor with mixed agonist/antagonist 
activity acting via endogenous estrogen receptors. Such potentially confounding effects should be 
controlled for, but >40% of publications that have used tamoxifen to generate conditional knockouts 
have not reported even the minimum appropriate controls. To highlight the importance of this issue, 
the present study investigated the long-term impacts of different doses of a single systemic tamoxifen 
injection on the testis and the wider endocrine system. We found that a single dose of tamoxifen less 
than 10% of the mean dose used for recombination induction, caused adverse effects to the testis and 
to the reproductive endocrine system that persisted long-term. These data raise significant concerns 
about the widespread use of tamoxifen induction of recombination, and highlight the importance of 
including appropriate controls in all pathophysiological studies using this means of induction.
Inducible Cre-lox transgenic systems are widely used to investigate gene function and study cell ontogeny via 
lineage tracing, as they allow for specific temporal control of genetic manipulation and avoidance of embry-
onic lethal phenotypes. The most commonly used approach has been to exploit the non-steroidal selective 
estrogen receptor modulator (SERM) tamoxifen, which has high affinity for estrogen receptors (ER), to create 
a ligand-dependent Cre recombinase. This Cre recombinase system consists of a fusion protein of Cre recombi-
nase and a mutated form of the human estrogen receptor (CreERT)1, 2. The CreERT recombinase cannot bind to 
endogenous estrogens and is only activated when bound to 4-hydroxytamoxifen, which is the active metabolite 
of tamoxifen3, 4; tamoxifen is attractive as an acute and specific inducer compound as it has a half-life of 6 hours in 
vivo5. In the absence of ligand, the CreERT is sequestered in the cytoplasm through heat-shock protein binding. 
When 4-hydroxytamoxifen enters the cell, it binds to CreERT and displaces the ligand-receptor complex from the 
heat-shock protein complex, allowing CreERT to translocate to the nucleus and drive recombination of a floxed 
target gene3, 4. Thus, excision of floxed chromosomal DNA is stringently controlled to allow for tight temporal and 
cell-specific control of genetic modification6.
Since the creation of the CreERT, newer ligand-dependent recombinases have been developed: CreERT2 and 
mER-Cre-mER, which have an increased efficiency of nuclear import compared to CreERT3, 7–9. However, the use 
of the tamoxifen-inducible Cre-lox system is not without potential drawbacks. Previously published literature has 
shown that tamoxifen doses commonly used to induce Cre-loxP recombination may continue to label significant 
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numbers of cells for weeks after tamoxifen treatment, possibly confounding the interpretation of time-sensitive 
studies using tamoxifen dependent models10–12. Recombination efficiency of Cre (measured by the number of 
cells that express a Cre-induced reporter protein) varies with factors such as: the route of tamoxifen adminis-
tration, the type of transgene, the tissue it is expressed in, mouse age and strain4. Recombination efficiency also 
increases with the dosage13 and the number of doses14 of tamoxifen administered. However, increasing the dose 
of tamoxifen can result in increased morbidity15, so exploitation of the system becomes an empirically defined 
compromise between several conflicting factors.
As a SERM, tamoxifen is not an inert compound for the control of Cre-loxP mediated recombination, but 
an active and well-established endocrine disruptor. SERMs are diverse, non-steroidal compounds with complex 
tertiary structures that allow them to bind to ERs16, 17. Once bound, tamoxifen can elicit either agonistic or antag-
onistic activity depending on the tissue in question, these differences arising because of differential ER expres-
sion, differential expression of co-regulatory proteins or ligand-specific ER conformational change that influence 
co-regulatory protein recruitment, which together modulate gene transcription16, 17. For example, tamoxifen acts 
as an agonist in the endometrium and the bone, but is a potent antagonist in breast tissue and thus is widely 
used to treat ER-positive breast cancer18–20. Tamoxifen behaves as a partial agonist when acting through estrogen 
receptor alpha (ESR1) but acts as an antagonist through estrogen receptor beta (ESR2)21, 22, thus adding another 
layer of complexity to the tissue-specific actions of tamoxifen.
The testis is an organ that both responds to estrogen signalling and produces endocrine hormones that impact 
almost all tissues of the body; it thus has utility as an exemplar organ for the systemic impacts of tamoxifen treat-
ment. Chronic treatment of adult male mice23 or rats24–28 with tamoxifen results in dose-dependent seminiferous 
tubule atrophy and therefore decreased fertility. Long term adverse effects on male reproductive function are also 
well-established to occur after neonatal administration of tamoxifen, including reduced testis and seminal vesicle 
(SV) size29, 30 and a reduction in fertility due to impaired spermatogenesis and decreased seminiferous tubule 
diameter31.
The present study investigates the long term impacts on the testis of a single tamoxifen injection at a range of 
doses in male mice at pubertal ages, including a dose well below that necessary to induce transgene expression 
and shows that even a single, low dose, systemic injection of tamoxifen induces persistent adverse changes to both 
spermatogenic and endocrine functions of the testis that can be detected weeks later. These findings raise con-
cerns relating to confounding effects from the use of tamoxifen-induction of transgenes, and highlight the impor-
tance of including appropriate controls in all genetic studies using tamoxifen-mediated transgene induction.
Results
Literature review of studies using tamoxifen inducible systems. To assess tamoxifen exposure as 
a confounding factor in experiments, we completed a PubMed review of the most recent four years of pub-
lished literature (January 2013 – December 2016) using the search term ‘tamoxifen inducible Cre mouse’. As the 
technology is now more than 20 years old, this period was chosen both to represent the most current practice, 
and also because sufficient time and understanding of the caveats of the system has developed to define best 
practice. This search identified 216 studies, 206 of which are fully accessible from a University of Edinburgh IP 
address. We assessed these 206 studies (including supplementary data) identifying those that reported the inclu-
sion of one or more of six appropriate treatment groups: 1 [Cre positive tam-treated] (41/206); 2 [Cre negative 
(or floxed alone) tam-treated] (105/206); 3 [Cre positive floxed positive tam-treated] (206/206); 4 [Cre positive 
vehicle-treated] (13/206); 5 [Cre negative (or floxed alone) vehicle-treated] (27/206); 6 [Cre positive floxed posi-
tive vehicle-treated] (64/206).
Whilst the gold standard would be to employ all six controls, we realise that for pragmatic reasons, in particu-
lar where the lines used have been well-characterised in previous publications, the absolute minimum controls 
that should be used when comparing within an experiment are control 1 and/or 2, a non-inducible transgenic 
mouse exposed to tamoxifen. 121/206 studies reported use of one or both of these a control, leaving 85 primary 
research studies published in the past four years at risk of undocumented confounders arising from the impact of 
tamoxifen exposure. Worryingly, 15 of these 85 studies reported Cre positive floxed positive vehicle-treated as the 
only control, whilst 36 of the 85 did not report or show data from any controls whatsoever.
Published tamoxifen treatment regimens for transgene induction vary widely. To evaluate the 
dose range and frequency of tamoxifen administration used in published studies for tamoxifen inducible Cre 
systems, fifty representative studies from 1998 onwards, covering all ages and dose regimens, were selected from 
an PubMed query for ‘Tamoxifen inducible Cre mouse’. These 50 studies yielded a total of 85 dose regimens 
(Supplementary Table 1). This showed that a wide range of tamoxifen doses have been determined as being opti-
mal in individual studies, even when mice were of similar ages; which is presumably dependent on previously 
determined efficiency of transgene recombination.
To empirically test the long-term impacts of single doses of tamoxifen we chose to inject a single dose of 
tamoxifen at either postnatal day (d)16 or 21 (early puberty for the mouse), which would permit us to examine 
both immediate impacts on physiology, but also enable us to track long-term impacts on reproductive develop-
ment and endocrine function into adulthood. Based on the average dose used in previously published literature 
(Supplementary Table 1), a single dose of 3 mg tamoxifen was considered to be representative.
A single dose of 3 mg tamoxifen induces adrenal but not testis transgene expression. We 
first focussed upon the dose of tamoxifen necessary for the induction of a Nestin-Cre-ERT2 transgene in the 
testis. Nestin is expressed in an interstitial cell population thought to be progenitor Leydig cells32 (Fig. 1a). 
Immunohistochemistry for YFP on testes from a Nestin-Cre YFP reporter line (designated NSYF) revealed YFP 
staining in interstitial Leydig cells when examined in adulthood (Fig. 1b), which became our positive control for 
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Figure 1. A single dose of 3 mg tamoxifen induces adrenal but not testis transgene expression. (a) A population 
of interstitial cells immunostain for nestin (red) in control testis sections at d35. (b) A population of interstitial 
cells immunostain for YFP (green) in testis sections from NSYF mice injected at d21 and examined at d35. (c) 
No YFP staining is seen in testis sections from d35 INYF mice treated with a single 3 mg dose of tamoxifen 
at d21. (d) YFP staining is seen in adrenal sections from a d35 INYF mouse treated with a single 3 mg dose of 
tamoxifen at d21 (green). (e) Localisation of Confetti fluorescent protein is restricted to small focal areas in d35 
IPRC testes treated with a single 3 mg dose of tamoxifen at d21(green). (f) Confetti protein is seen in adrenal 
sections from d35 IPRC mice treated with a single 3 mg dose of tamoxifen at d21 (green). Scale bars are all 
100 µm.
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the predicted expression pattern if Nestin-CreERT2 was induced. A tamoxifen-inducible Nestin-Cre (Nestin-Cre/
ERT2) YFP reporter line (designated INYF) was treated with a single 3 mg dose of tamoxifen at d21. This did not 
induce YFP expression in the testis by d35 (Fig. 1c), however induction of adrenal expression of YFP was found 
(Fig. 1d), suggesting that 3 mg induces transgene expression in some target organs but not others. To confirm 
that this was not transgene-specific, we repeated the treatment using a different Cre line known to mark the same 
cell-types, iPdgfra-Cre/ERT2, bred to a different lineage tracing reporter, R26R-Confetti (designated IPRC), with 
similar results (Fig. 1e,f). On this basis we concluded that this is close to the minimum dose necessary to induce 
transgene expression in this line.
Despite exposing the mice to a tamoxifen dose that was unable to induce transgene recombination in the testis, 
all six tamoxifen-treated INYF mice injected at d21 were cryptorchid when dissected at 5 weeks of age (Fig. 2a), 
whereas the testes of all six INYF vehicle controls were normally descended into the scrotum (p = 0.0022, Fisher’s 
exact test). However, when mice injected at d21 were examined at 7 weeks of age both all seven tamoxifen-treated 
and all seven untreated mice had normally descended testes. Despite this, both the testes (Fig. 2b) and seminal 
vesicles (SV) (Fig. 2c) of the tamoxifen-treated mice were visibly smaller than their non-treated littermate con-
trols at 7 weeks.
A single dose of 3 mg tamoxifen has long term endocrine effects in male mice. To focus on the 
effects of tamoxifen and exclude any possible confounding factors arising from transgene induction, our fur-
ther studies used wild-type C57bl/6 mice. Consistent with data from the INYF line, six out of six C57bl/6 mice 
injected with 3 mg tamoxifen at d16 were also cryptorchid at 5 weeks of age, compared to descended testes in six 
out of six vehicle injected mice at this age (p = 0.0022, Fisher’s exact test), whereas testicular descent had occurred 
by 7 weeks of age in six out of six of both vehicle and tamoxifen injected groups. However, at the latter age, tamox-
ifen treated mice exhibited significant reductions in body weight (Fig. 2d), testis weight (Fig. 2e), and SV weight 
(Fig. 2f); SV size is a reliable biomarker of circulating testosterone levels but is also directly sensitive to estro-
genic effects33. Despite this, circulating testosterone levels were not significantly different in tamoxifen-exposed 
mice compared to the controls (Fig. 2g), however LH levels were significantly increased, indicating compensated 
Leydig cell failure (Fig. 2h). Together these data show that a single dose of tamoxifen similar to the concentration 
usually given to induce a transgene elicits long term adverse effects on testis size and endocrine function five 
weeks after tamoxifen exposure.
A single dose of 3 mg tamoxifen has long term effects on spermatogenesis. When examined at 7 
weeks of age, mice treated with tamoxifen at d16 had grossly normal testicular histology, with no major changes 
to seminiferous tubule organisation (Fig. 3A,B). However, the seminiferous tubules of tamoxifen treated mice had 
Figure 2. A single dose of 3 mg tamoxifen has long term endocrine effects in male mice. (a) INYF mice injected 
with 3 mg tamoxifen at d21 are cryptorchid at 5 weeks whereas the testes of non-treated INYF controls are not. 
(b) Testes of the d21 INYF tamoxifen-treated mice are visibly smaller than their non-treated littermate controls 
when examined at 7 weeks. (c) Seminal vesicles of the d21 INYF tamoxifen-treated mice are visibly smaller 
than their non-treated littermate controls when examined at 7 weeks. (d) C57bl/6 mice treated with a single 
systemic 3 mg dose of tamoxifen at d16 have significant reductions in body weight, (e) testis weight and (f) SV 
weight when examined at 7 weeks. (g) C57bl/6 mice injected with tamoxifen at d16 have no difference in plasma 
testosterone at 7 weeks compared to the controls. (h) Plasma LH is significantly increased in tamoxifen-treated 
mice. Graph values are group means where n ≥ 7, error bars are SEM.
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a significantly smaller diameter (Fig. 3C) and a significant reduction in both Sertoli cell (Fig. 3D) and total germ 
cell volume per testis (Fig. 3E). Although the numbers of spermatogonia, spermatocytes and round spermatids 
per Sertoli cell were unchanged in tamoxifen-exposed animals (Fig. 3F–H), the number of elongate spermatids 
per Sertoli cell was significantly reduced. (Fig. 3I). Testes from tamoxifen-treated mice also showed significant 
reductions in testicular expression of the spermatocyte marker Dkkl1 (Fig. 3J) and the spermatid marker Tnp134–36 
(Fig. 3K), as well as a visibly reduced area of immunohistochemical staining for the spermatid marker PGK 1/2 
(Fig. 3L). These findings show that a single early pubertal exposure to tamoxifen results in a permanent reduction 
in Sertoli cell number (and a consequential reduction in total germ cell number). However, in addition to this 
overall change, tamoxifen exposure resulted specifically in a significant loss of spermatids per Sertoli cell, which 
will result in a corresponding reduction in number of sperm produced.
A single dose of 1 mg or 250 µg tamoxifen does not delay testis descent, yet still has persistent 
effects on the male reproductive system. Our findings cannot exclude that the spermatogenic changes 
observed in the 3 mg tamoxifen treatment group are secondary to the delayed testicular descent induced by 
tamoxifen exposure as this is known to impact spermatogenesis and possibly endocrine function37, 38. To address 
Figure 3. A single dose of 3 mg tamoxifen at d16 has long term effects on spermatogenesis. (A,B) C57bl/6 mice 
treated with tamoxifen at d16 have visibly normal testicular histology, with no gross changes to seminiferous 
tubule organisation at 7 weeks compared to controls. (C) The seminiferous tubules of tamoxifen-treated mice 
have a significantly smaller diameter than controls (n = 3 mice, 50 measurements per testis, error bars are 
SEM). Stereological cell counting reveals a significant reduction in (D) Sertoli cell volume and (E) germ cell 
volume per testis in tamoxifen-treated mice. (F–H) The number of spermatogonia, spermatocytes and round 
spermatids per Sertoli cell is unchanged. (I) The number of elongate spermatids per Sertoli cell is significantly 
reduced (cell counting measurements n = 4 mice, error bars are SEM). Testes from tamoxifen-treated mice 
also show significant reductions in the expression of (J) the spermatocyte marker Dkkl1 and (K) the spermatid 
marker Tnp1 (qPCRs n = 7, error bars are SEM). (L) Testes from tamoxifen-treated mice have a visibly reduced 
area of immunohistochemical staining for the spermatid marker PGK 1/2.
www.nature.com/scientificreports/
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this, we reduced the dose of tamoxifen used to a single dose of 1 mg or 250 µg (~12-fold less than that required to 
induce transgene expression), which pilot studies had shown did not induce delayed testicular descent. Consistent 
with this, the testes of mice treated with a single dose of 1 mg or 250 µg tamoxifen did not show a delay in testis 
descent compared to vehicle-treated controls (four out of four vehicle, five out of five 1 mg treated and five out of 
five 250 µg treated mice had descended testicles when examined at 5 weeks). However, as had been found with 
the 3 mg tamoxifen dose, mice treated on d16 with 1 mg or 250 µg groups both exhibited a significant reduction 
in SV weight and testis weight (although not body weight) at 7 weeks of age (five weeks after dosing) (Fig. 4a–c). 
No grossly visible reduction in spermatogenesis (Fig. 5A–C) or in seminiferous tubule diameter (Fig. 5D) was 
observed at 7 weeks of age in mice treated with 1 mg or 250 µg tamoxifen. Unlike the 3 mg treatment, there was 
no significant change in Sertoli cell volume per testis in either the 1 mg or 250 µg treatment groups (Fig. 5E), but 
the 1 mg tamoxifen-treated group had a significantly lower total germ cell volume per testis (Fig. 5F). Despite this 
overall change, the numbers of spermatogonia, spermatocytes, round and elongating spermatids per Sertoli cell 
were not significantly different between controls and tamoxifen-exposed animals (Fig. 5G–J). Despite this, testes 
from 1 mg tamoxifen treated animals showed significant reductions in the expression of both Dkkl1 (Fig. 5K) 
and Tnp1 (Fig. 5L) as well as visibly reduced immunohistochemical staining for PGK 1/2 compared to controls 
(Fig. 5M,O). Testes of mice treated with 250 µg tamoxifen showed a significant reduction in Tnp1 (Fig. 5K), but 
not Dkkl1 (Fig. 5L) but there was no conclusive change in the intensity of PGK 1/2 immunostaining (Fig. 5M–N). 
Together these data show that even extremely low exposure to tamoxifen continues to impact spermatogenesis 
several weeks later.
A single dose of 1 mg tamoxifen alters Leydig cell maturation and function. Since endocrine 
disruption in the testis may result in changes to Leydig cell maturation39, the number and maturation state of 
Leydig cells at 7 weeks after an injection of 1 mg or 250 µg tamoxifen at d16 was investigated. Although Leydig 
cell number per testis was not significantly altered (Fig. 6A), transcript expression of the established maturation 
markers Insl3, Ptgds and Hsd3b639 was significantly decreased in both groups of tamoxifen-treated mice com-
pared to controls (Fig. 6B–D), demonstrating that even at extremely low single doses, tamoxifen is able to perturb 
testicular endocrine function many weeks later.
As Leydig cell maturation state can affect overall function and steroidogenic enzyme expression, the expres-
sion of steroidogenic enzyme genes was investigated at 7 weeks of age in 1 mg and 250 µg tamoxifen treated 
mice. Expression of Cyp11a1 and Hsd17b3 were not significantly altered (Fig. 6E–F), but expression of Hsd3b1 
was increased, though only in the 250 µg dose group (Fig. 6G), and the expression of Star was dose-dependently 
reduced (Fig. 6H). Plasma testosterone was not significantly different in either tamoxifen dose group compared 
to controls (Fig. 6I), but plasma LH was dose-dependently increased in the tamoxifen-exposed mice com-
pared to controls (Fig. 6J), indicating compensated Leydig cell failure. The expression of Lhcgr in the testes of 
tamoxifen-exposed animals was also increased, although not significantly (Fig. 6K). Together these data demon-
strate long term impacts on the endocrine function of the testes as a consequence of exposure to a single low dose 
of tamoxifen 5 weeks previously.
A single dose of 1 mg tamoxifen changes the androgen/estrogen balance in the testis. Both 
androgens and estrogens are important in normal testis function as is the balance between the two40, 41, and as 
tamoxifen is a SERM it could disrupt this balance. To address this, we investigated the expression of steroid 
nuclear receptor genes and their downstream target genes in the testes of tamoxifen-exposed mice, five weeks 
after exposure. Expression of Esr1 was dose-dependently decreased by tamoxifen treatment (Fig. 7A). However, 
expression of the downstream Esr1 target gene Gas6 was not significantly altered at either tamoxifen dose 
(Fig. 7B). Both Esr2 expression (Fig. 7C) and expression of the downstream Esr2 target gene Faah (Fig. 7D) were 
significantly decreased in the 1 mg tamoxifen group compared to controls, but unchanged in the 250 µg dose 
Figure 4. A single dose of 1 mg or 250 µg tamoxifen at d16 does not delay testis descent, yet still reduces testis 
weight. (a) INYF mice treated with either 1 mg or 250 µg tamoxifen at d16 do not have a significant change in 
body weight compared to controls at 7 weeks. (b) Both 1 mg and 250 µg groups have a significant reduction in 
testis weight compared to controls at 7 weeks. (c) Both 1 mg and 250 µg groups have a significant reduction in 
SV weight compared to controls at 7 weeks. (All measurements n ≥ 6, error bars are SEM).
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group. Finally, Ar expression was not significantly altered in tamoxifen dose group (Fig. 7E), but expression of 
the downstream AR target gene Rhox5 was significantly decreased in the 1 mg tamoxifen group (Fig. 7F). Taken 
together, these results demonstrate that a single low dose of tamoxifen in early pubertal life may significantly 
disrupt the androgen:estrogen balance within the testes in young adulthood.
Discussion
There is an abundant literature that demonstrates that administration of estrogens to male rodents is able to 
induce both transient and long-term/permanent adverse changes to various reproductive organs and their func-
tions, in particular impairment of spermatogenesis and steroid hormone production42–44. These effects are gener-
ally dose-dependent and can occur after exposure at various ages, although the nature and severity of effects may 
vary with the age of estrogen exposure, with perinatal exposure usually resulting in the most severe long-lasting 
consequences42–44. It seems that the most severe effects of estrogens in male rodents are mediated via ESR1 as 
deletion of this gene results in abrogation of the adverse estrogen effects, including on the testis44. Tamoxifen is 
a SERM with tissue-specific agonistic or antagonistic estrogen effects, but in the testis and generally throughout 
the male reproductive tract, tamoxifen acts as a potent estrogen agonist30, 45, 46. Consistent with this, tamoxifen 
administration is able to mimic at least some of the adverse male reproductive effects of estrogens described 
above30, 45, although these have not been studied in great detail and the effects in mice may vary between strains45. 
Tamoxifen is also thought to induce cellular stress in neurons, vasculature and ependyma by binding cholesterol 
epoxide hydrolase, highlighting that some detrimental effects of tamoxifen may not be mediated by estrogen 
receptors47. However this effect can be abrogated by delivery of tamoxifen in a vitamin E rich vehicle such as 
wheat germ oil.
The present findings, showing that early pubertal exposure of mice to a single dose of tamoxifen is able to 
dose-dependently induce adverse testicular effects, confirm and extend the earlier findings outlined above. 
However, the motivation for the present studies was not to add to this literature but to investigate the potential 
for tamoxifen induction of Cre recombinase in transgenic studies to induce adverse reproductive and endocrine 
functional changes in male mice that might be misinterpreted as resulting from transgene manipulation. Our 
findings show that such confounding effects of tamoxifen are likely to be a major issue for any study that involves 
Figure 5. A single dose of 1 mg or 250 µg tamoxifen at d16 has long term effects on spermatogenesis. (A–C) 
No visible reduction in spermatogenesis at 7 weeks is observed when testicular histology is examined in 
mice treated with 1 mg or 250 µg tamoxifen at d16. (D) No reduction in seminiferous tubule diameter is 
observed when testicular histology is examined in mice treated with 1 mg or 250 µg tamoxifen (n = 3 mice, 50 
measurements per testis, error bars are SEM). (E) Stereological cell counting reveals no significant change in 
Sertoli cell volume per testis in 1 mg and 250 µg groups compared to control. (F) Total germ cell volume per 
testis is reduced in 1 mg tamoxifen-treated mice but not in 250 µg tamoxifen-treated mice. (G–J) The number 
of spermatogonia, spermatocytes, round and elongating spermatids per Sertoli cell is unchanged (cell counting 
measurements n = 5 mice, error bars are SEM). (K) 1 mg tamoxifen-treated testes show a significant reduction 
in Dkkl1, whereas 250 µg tamoxifen-treated testes do not. (L) Both 1 mg and 250 µg tamoxifen-treated testes 
have a significant reduction in Tnp1. (qPCRs n = 5, error bars are SEM). (M–O) 1 mg tamoxifen treated testes 
have visibly reduced immunohistochemical staining for the spermatid marker PGK 1/2 compared to controls 
whereas 250 µg tamoxifen-treated testes do not.
www.nature.com/scientificreports/
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evaluation of reproductive endpoints but also raises concerns where endpoint evaluation involves the study of tis-
sues that are modulated by estrogens (or androgens) in view of the potential for both direct effects (of tamoxifen 
itself) and indirect effects (resulting from altered Leydig cell steroidogenic function in the testes); such effects may 
also vary between different strains45. We suggest below that appropriate controls are essential to guard against 
potential confounding effects.
The tamoxifen-inducible Cre system is a popular transgenic tool for controlling the disruption of gene expres-
sion at a specific time and in a specific cell type. However, despite a large number of studies suggesting that 
tamoxifen is an endocrine disruptor with long term effects not just on the male reproductive system but also 
on the wider body, our literature survey shows that many studies still do not include appropriate controls. In 
this study we show that a single early treatment of pubertal male mice with a dose of tamoxifen that is a third or 
even a twelfth of the mean single dose used for recombination induction in mice of this age group, can have long 
term effects on testis physiology and function. Moreover, each of the principle cell types of the testis (Sertoli, 
germ, Leydig) were adversely affected five weeks after dosing. Of particular concern is the persistent disruption 
of Leydig cell maturation and function after tamoxifen exposure, including possible resetting of the androgen/
estrogen balance in the testis, based on the changes in steroid hormone receptor and target gene expression. Since 
most body tissues also express androgen and estrogen receptors and are exposed to the sex steroids produced by 
Figure 6. A single dose of 1 mg tamoxifen at d16 alters Leydig cell maturation and function in adulthood. 
(A) Leydig cell number per testis at 7 weeks was not significantly different to controls in both 1 mg and 250 µg 
INYF mice tamoxifen-treated mice (n ≥ 5, error bars are SEM). Expression of the maturation markers (B) 
Insl3, (C) Ptgds and (D) Hsd3b6 is significantly decreased in both doses of treated mice compared to vehicle 
controls. Expression of the steroidogenic enzyme genes (E) Cyp11a1 and (F) Hsd17b3 are unchanged in 
tamoxifen-treated testes. (G) The expression of Hsd3b1 is significantly increased in the 250 µg group but not 
the 1 mg group. (H) The expression of Star is significantly decreased in the 1 mg group but not the 250 µg group. 
(I) Plasma testosterone is not significantly different in treated mice compared to controls. (J) Plasma LH is 
significantly increased in the 1 mg (but not 250 µg) treated mice compared to controls. (K) The expression of 
Lhcgr in the testes of treated controls is also increased in the 1 mg but not 250 µg groups. (All qPCRs n ≥ 5, all 
hormone measurements n ≥ 7, error bars are SEM).
Figure 7. A single dose of 1 mg tamoxifen at d16 changes the androgen/estrogen balance in the testis. (A) 
Expression of the estrogen receptor α transcript Esr1 is significantly decreased at 7 weeks after a single 1 mg (but 
not 250 µg) tamoxifen treatment at d16 in INYF mice. (B) Gas6 is not significantly changed after either a 1 mg or 
250 µg dose. (C) Esr2 expression is significantly decreased after a 1 mg tamoxifen dose but not a 250 µg dose. (D) 
Faah expression is significantly decreased after a 1 mg tamoxifen dose but not a 250 µg dose. (E) Ar expression 
is not significantly different in either group. (F) Rhox5 is significantly decreased in the 1 mg treated group but 
unchanged in the 250 µg treated group (All qPCRs n ≥ 5, error bars are SEM).
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the testes, it is considered likely that a single dose of tamoxifen may also affect aspects of systemic physiology and 
endocrinology, some of which could be confounders in transgene induction studies.
Armed with this information, we suggest that transgenic studies using tamoxifen should be designed with six 
experimental groups: 1 [Cre positive tam-treated]; 2 [Cre negative (or floxed alone) tam-treated]; 3 [Cre postive 
floxed positive tam-treated]; 4 [Cre positive vehicle-treated]; 5 [Cre negative (or floxed alone) vehicle-treated]; 6 
[Cre positive floxed positive vehicle-treated]. Whilst with hindsight and good research practices this study design 
appears obvious, as we have shown, the use of all six experimental groups is rarely seen in published studies, with 85 
of the 206 primary research studies published in the past four years at risk of undocumented confounders arising 
from the impact of tamoxifen exposure. Worryingly, 15 of these 85 studies reported [Cre positive floxed positive 
vehicle-treated] as the only control, whilst 36 of the 85 did not report or show data from any controls whatsoever.
A further concern highlighted by this literature search is that, even in cases where a tamoxifen-treated 
control was employed, an equivalent vehicle-treated control was often absent. Without the additional use of 
vehicle controls alongside of tamoxifen only controls, correct interpretation of results obtained from gene dele-
tion studies could be confounded, as the experimenter determines the impact of gene ablation in an entirely 
tamoxifen-exposed colony, rather than against normal physiological and endocrine conditions. The severities of 
off-target effects caused by tamoxifen are also likely to vary based on the mouse strain used45, the age of experi-
mental animals, the estrogen (and androgen) responsiveness of the tissue of interest and the tamoxifen dose used. 
Therefore, it is essential to at least carry out a small pilot study with tamoxifen and vehicle controls to catalogue 
the off-target effects of tamoxifen and how they might impact on future studies.
Since the mice in our study were examined in early adulthood, we do not know whether the tamoxifen-induced 
changes that we report would persist and become worse as the mice age or whether they would resolve and the 
disrupted testis parameters return to normal. However, we consider the latter unlikely based on the extensive 
evidence of estrogen effects on the male43, 44 and, in general any adverse functions evident in young adult male 
rodents persist or worsen with age, rather than resolving39. In keeping with this, a study involving five consecutive 
daily injections of 3 mg tamoxifen from d50 to d54 in mice, found decreases in ventral prostate weight, Leydig cell 
Insl3 expression and seminiferous tubule diameter, changes that were still evident 50 days later48.
In conclusion, this study identifies numerous caveats associated with the use of tamoxifen as an inducer of 
transgene expression, and highlights the acute sensitivity of the pubertal mouse testis to even a single low dose of 
tamoxifen. The adverse changes that are induced by such treatment are still evident many weeks after treatment, 
and by inference are likely to equally apply across other androgen and estrogen-sensitive tissues. These findings 
should be taken into consideration when planning experiments using this valuable transgenic tool.
Materials and Methods
Ethics Statement. All experimental procedures were approved by Edinburgh University Ethical Review 
Committee and conducted under licenced approval of the UK Home Office, project licence 60/4200, in compli-
ance with the Animals (Scientific Procedures) Act, 1986.
Mouse husbandry. Mice were kept in a 12-hour light/dark regimen with humidity maintained at 55% and 
temperature between 20 and 25 °C. Food and water were available ad libitum. Mice were fed a soy-free diet man-
ufactured by Special Diet Services (SDS) and distributed by DBM (Scotland) Ltd.
Transgenic lines used. Male congenic C57BL/6 J mice carrying a random insertion of either a non-inducible 
Nestin-Cre49, an inducible Nestin-Cre/ERT2 transgene50, or inducible iPDGFRa-Cre/ERT2 were used. Reporter lines 
used were R26R-YFP51 and R26R-Confetti52. Homozygous female R26R-EYFP mice were mated to male Nestin-Cre 
mice to produce the ‘NSYF’ line and male Nestin-Cre/ERT2 Cre recombinase mice to produce the ‘INYF’ line. 
Homozygous female R26R-Confetti mice were mated to male iPDGFRa-Cre/ERT2 mice to produce the IPRC line.
Genotyping of animals. Mice were genotyped for inheritance of Cre Recombinase as previously 
described53. PCR amplification products were resolved using a QiaXcel capillary system (Qiagen, UK). An ampli-
con of 102 bp indicated inheritance of the Cre Recombinase transgene.
Tamoxifen treatments. Tamoxifen (T5648, Sigma-Aldrich) solutions were made up to final concentra-
tions of 1 mg/mL or 3 mg/mL. The powder was partially dissolved in sterile dimethyl sulfoxide (DMSO; D2650 
Sigma-Aldrich) by gentle heating and vortexing, then diluted 1:10 in peanut oil (P2144; Sigma-Aldrich) and 
sonicated for full dissolution for a maximum of 5 minutes. Solutions were stored at −20 °C in opaque containers 
for a maximum of one month. Defrosted aliquots in use were stored concealed from light at 4 °C for a maximum 
of one week. Injections were administered intraperitoneally (i.p.) at 25 µl–200 µl depending on dose. Control 
animals were injected with 10% DMSO/90% peanut oil solution. Injections were performed blind to genotype.
Recovery of tissues. Mice were euthanised by inhalation of carbon dioxide and subsequent cervical dislo-
cation at 10:00 h. Testes were either fixed in Bouin’s fixative (Clin-Tech, Guildford, UK) for 6 hours or frozen on 
dry ice before being transferred to a −80 °C freezer for storage.
Quantification of plasma hormone levels. Immediately after culling, blood was collected from mice 
by cardiac puncture with a syringe and needle pre-treated with heparin. Plasma was separated by centrifugation 
and stored at −80 °C. Testosterone was measured using an ELISA kit (DEV9911; Demeditec Diagnostics, Kiel, 
Germany). LH was measured using an in-house designed ELISA as previously described54. Samples for each 
treatment group or age group were analysed together.
www.nature.com/scientificreports/
1 0Scientific REPORTS | 7: 8991  | DOI:10.1038/s41598-017-09016-4
Histology and immunohistochemistry. Fixed tissues were processed and embedded in paraffin wax, 
and 5 μm sections were used for histological analysis. Sections of testis were stained with haematoxylin and eosin 
using standard protocols. Immunostaining was performed using a tyramide fluorescent immunostaining method 
as previously described55. Primary antibodies used were mouse α-nestin (Abcam ab6142), Rabbit α-GFP (Abcam 
#ab6556) or rabbit α-Pgk1/2 (Santa Cruz sc-28784).
Stereological quantification of Leydig cell numbers. To determine the numbers of 3βHSD-positive 
Leydig cells per testis, the point-counting method was used as described previously56, 57. Image-Pro 7.0 with 
Stereologer plug-in software (MagWorldwide; Wokingham, UK) was used to visualise the immunostaining 
on-screen and carry out stereological quantification. A Leitz × 60 objective fitted to a Zeiss Axio-Imager micro-
scope (CarlZeiss Ltd; Welwyn Garden City, UK) fitted with a HVC20 camera (Hitachi Denshi Europe, Leeds, UK) 
was the hardware used in this process. 3βHSD immunostaining was used to identify Leydig cells (LCs).
Stereological quantification of germ cell numbers. Standard stereological techniques involving point 
counting of cell nuclei were used to determine the nuclear volume per testis of Sertoli cells and different matura-
tional stages of germ cells, as previously described58.
Stereological quantification of seminiferous tubule diameter. Seminiferous tubules were measured 
using a previously published method53. Only tubules with circular cross-sections were measured and measure-
ments from 50 tubules per animal were recorded to have an accurate representation of seminiferous tubule diam-
eter measurements.
Preparation of testis cDNA. RNA was isolated from frozen testes using the RNeasy Mini extraction kit 
with RNase-free DNase on-the-column digestion kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. Due to changes in testis cell composition and size during normal development or due to the impact 
of gene deletion/treatment, 5 ng of luciferase mRNA (Promega, UK) was added per testis prior to RNA extraction 
as an external control to allow for direct comparison between samples59. RNA was quantified using a NanoDrop 
1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) andcDNA was prepared using the 
SuperScript VILO cDNA synthesis kit (Life Technologies) according to manufacturer’s instructions.
Quantitative RT-PCR (qPCR). qPCR was performed on testis cDNA using an ABI Prism 7900 Sequence 
Detection System (Applied Biosystems) and the Roche Universal Probe library (Roche, Welwyn, UK). Roche 
UPL probes are labelled with 6-carboxyfluorescein (FAM) and were run as a multiplex with a luciferase assay59 in 
which the probe is labelled with NED. The assays for Lhcgr, Cyp11a1, Hsd3b1, Hsd3b6, Hsd17b3, Cyp19a1, Insl3, 
Ptgds39 and Rhox558 have been previously published. New assays are detailed in Table 1. Resulting data were ana-
lysed using the ΔΔCt method60. All gene expression data was expressed relative to Luciferase mRNA expression. 
In the cases where Leydig cell-counts were carried out, relative mRNA expression was then corrected for Leydig 
cell numbers for Leydig cell-specific genes.
Statistical analyses. All analyses were performed using GraphPad Prism version 6 (GraphPad Software 
Inc, San Diego, CA, USA). Values are expressed as means ± SEM. Distribution of collected data was determined 
by a D’Agostino-Pearson normality test. If data was normally distributed, a two-tailed, unpaired t-test was used 
to compare two groups, unless a specific hypothesis was being tested, in which case a one-tailed test was used. 
Non-parametric data were compared using a Mann-Whitney U test. For 3 or more normally-distributed groups, 
a one-way analysis of variance (ANOVA) test followed by the Bonferroni post-hoc test was carried out. The 
Kruskal–Wallis test was carried out for 3 or more groups in case of non-parametric data. For analysis of cryptor-
chidism rates, Fisher’s exact test was performed.
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